Data from the Phase 1 clinical trial of novel KCNK13 inhibitor showed good CNS exposure and was generally well-toleratedProprietary NETSseq platform explores the key potential role of astrocytes ...

Final presentation date and time to be confirmed About Cytokinetics Cytokinetics is a specialty cardiovascular biopharmaceutical company, building on its over 25 years of pioneering scientific ...

Hot Line Presentation of MAPLE-HCM to Elaborate on Positive Topline Results in Patients with Obstructive Hypertrophic Cardiomyopathy ...